SAN

85.44

-0.67%↓

MRK1

119.8

+2.39%↑

SHL.DE

42.31

-0.47%↓

ARGX

795.4

+1.87%↑

PHIA

24.08

-0.5%↓

SAN

85.44

-0.67%↓

MRK1

119.8

+2.39%↑

SHL.DE

42.31

-0.47%↓

ARGX

795.4

+1.87%↑

PHIA

24.08

-0.5%↓

SAN

85.44

-0.67%↓

MRK1

119.8

+2.39%↑

SHL.DE

42.31

-0.47%↓

ARGX

795.4

+1.87%↑

PHIA

24.08

-0.5%↓

SAN

85.44

-0.67%↓

MRK1

119.8

+2.39%↑

SHL.DE

42.31

-0.47%↓

ARGX

795.4

+1.87%↑

PHIA

24.08

-0.5%↓

SAN

85.44

-0.67%↓

MRK1

119.8

+2.39%↑

SHL.DE

42.31

-0.47%↓

ARGX

795.4

+1.87%↑

PHIA

24.08

-0.5%↓

Search

Fagron

Uždarymo kaina

SektoriusSveikatos priežiūra

20.95 0.24

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

20.85

Max

21

Pagrindiniai rodikliai

By Trading Economics

Pajamos

5.4M

46M

Pardavimai

34M

476M

P/E

Sektoriaus vid.

17.992

79.874

Dividendų pajamingumas

1.69

Pelno marža

9.569

Darbuotojai

3,989

EBITDA

16M

87M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+20.59% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

1.69%

2.31%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

96M

1.5B

Ankstesnė atidarymo kaina

20.71

Ankstesnė uždarymo kaina

20.95

Naujienos nuotaikos

By Acuity

70%

30%

351 / 374 reitingas Healthcare

Fagron Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-02 17:29; UTC

Pagrindinės rinkos jėgos
Įsigijimai, susijungimai, perėmimai

Laurentian Bank Shares Hit Two-Year High on Plans for Break-Up, Takeover

2025-12-02 16:21; UTC

Uždarbis

Scotiabank Aiming for Earnings Growth After Capital Markets Buoy Results in Latest Quarter -- Update

2025-12-02 16:18; UTC

Uždarbis

Correction to Scotiabank Quarterly Earnings Buoyed Article

2025-12-02 23:53; UTC

Rinkos pokalbiai

Nikkei May Rise After Gains on Wall Street -- Market Talk

2025-12-02 22:48; UTC

Uždarbis

Marvell's Stock Soars On Data Center Forecast -- Barrons.com

2025-12-02 22:12; UTC

Rinkos pokalbiai

Australian 3Q GDP To Show Modest Recovery In Play -- Market Talk

2025-12-02 22:03; UTC

Rinkos pokalbiai

Minerals 260's Resource Upgrade Looks Impressive -- Market Talk

2025-12-02 22:00; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-12-02 22:00; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-02 22:00; UTC

Rinkos pokalbiai

Fletcher Building Loses Bull Due to Tame Housing-Market Recovery -- Market Talk

2025-12-02 21:56; UTC

Uždarbis

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2025-12-02 21:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-12-02 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-02 21:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-12-02 21:44; UTC

Uždarbis

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2025-12-02 21:38; UTC

Rinkos pokalbiai

Sky Network TV Has Path to Grow Dividend by 33% -- Market Talk

2025-12-02 21:19; UTC

Uždarbis

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2025-12-02 20:06; UTC

Rinkos pokalbiai

Oil Futures Fall Amid Russia-Ukraine Peace Talks -- Market Talk

2025-12-02 19:55; UTC

Rinkos pokalbiai

Natural Gas Futures Fall Amid Uncertain Weather Forecasts -- Market Talk

2025-12-02 19:53; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

2025-12-02 19:53; UTC

Rinkos pokalbiai
Uždarbis

Scotiabank ROE Target Viewed as Possibly Conservative -- Market Talk

2025-12-02 19:24; UTC

Rinkos pokalbiai

Analysts Project Uptick in U.S. Ethanol Stocks -- Market Talk

2025-12-02 19:06; UTC

Rinkos pokalbiai

Precious Metals Step Back After Silver Sets Record -- Market Talk

2025-12-02 18:27; UTC

Įsigijimai, susijungimai, perėmimai

Kraken to Acquire Backed Finance AG

2025-12-02 17:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-02 17:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-12-02 15:17; UTC

Rinkos pokalbiai

Natural Gas Extends Gains Amid Cold Weather -- Market Talk

2025-12-02 14:47; UTC

Rinkos pokalbiai

BOE Likely to Cut Rates Further, Weakening Sterling -- Market Talk

2025-12-02 14:38; UTC

Rinkos pokalbiai

Silver Steps Back From Record Levels -- Market Talk

2025-12-02 14:31; UTC

Rinkos pokalbiai
Uždarbis

Scotiabank Strong Quarter Driven By Capital Markets Growth -- Market Talk

Akcijų palyginimas

Kainos pokytis

Fagron Prognozė

Kainos tikslas

By TipRanks

20.59% į viršų

12 mėnesių prognozė

Vidutinis 19.5 EUR  20.59%

Aukščiausias 19.5 EUR

Žemiausias 19.5 EUR

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Fagron kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

351 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Fagron

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
help-icon Live chat